A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy.
Metastatic Pancreatic Cancer
DRUG: Fluzoparib|DRUG: Placebo
PFS by Blinded Independent Central Review (BICR) Using RECIST v1.1, Progression-Free-Survival, up to 3 years
ORR by BICR Using RECIST v1.1, Objective Response Rate, up to 3 years|DCR by BICR Using RECIST v1.1, Disease Control Rate, up to 3 years|DoR by BICR Using RECIST v1.1, Duration of Response, up to 3 years|PFS by Investigators Using RECIST v1.1, Progression-Free-Survival, up to 3 years|ORR by Investigators Using RECIST v1.1, Objective Response Rate, up to 3 years|DCR by Investigators Using RECIST v1.1, Disease Control Rate, up to 3 years|DoR by Investigators Using RECIST v1.1, Duration of Response, up to 3 years|OS, Overall-Survival, up to 3 years|Number of participants with treatment-emergent adverse events, The number and proportion of subjects experiencing treatment-emergent adverse events (TEAE), From the first drug administration to within 30 days for the last drug dose
The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy.